PDCD1 and neoplasm: To evaluate the combination potential of CD8-mIL2 and anti–PD-1, T3 tumor-bearing mice were treated on day 12, at which time tumors became resistant to anti–PD-1 therapy (Fig. 5A; ref. 38).